1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Lyme Disease Diagnostics Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Lyme Disease Diagnostics Market Analysis and Forecast, 2017-2031
4.4.1. Market Revenue Projection (US$ Mn)
5. Key Insights
5.1. Innovations in Diagnostic Testing for Lyme disease
5.2. Incidence and Prevalence of Lyme Disease
5.3. Regulatory Scenario by Region/Globally
5.4. COVID-19 Pandemic Impact on Industry (Value Chain and Short/Mid/Long Term Impact)
6. Global Lyme Disease Diagnostics Market Analysis and Forecast, by Diagnostic Test
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Diagnostic Test, 2017-2031
6.3.1. Serological Test
6.3.1.1. ELISA
6.3.1.2. Western Blot
6.3.2. Polymerase Chain Reaction (PCR) test
6.3.3. Others
6.4. Market Attractiveness Analysis, by Diagnostic Test
7. Global Lyme Disease Diagnostics Market Analysis and Forecast, by Sample
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Sample, 2017-2031
7.3.1. Blood
7.3.2. Cerebrospinal Fluid (CSF)
7.3.3. Others
7.4. Market Attractiveness Analysis, by Sample
8. Global Lyme Disease Diagnostics Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by End-user, 2017-2031
8.3.1. Hospitals
8.3.2. Diagnostic Laboratories
8.3.3. Others
8.4. Market Attractiveness Analysis, by End-user
9. Global Lyme Disease Diagnostics Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2017-2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Lyme Disease Diagnostics Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Diagnostic Test, 2017-2031
10.2.1. Serological Test
10.2.1.1. ELISA
10.2.1.2. Western Blot
10.2.2. Polymerase Chain Reaction (PCR) test
10.2.3. Others
10.3. Market Value Forecast, by Sample, 2017-2031
10.3.1. Blood
10.3.2. Cerebrospinal Fluid (CSF)
10.3.3. Others
10.4. Market Value Forecast, by End-user, 2017-2031
10.4.1. Hospitals
10.4.2. Diagnostic Laboratories
10.4.3. Others
10.5. Market Value Forecast, by Country, 2017-2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Diagnostic Test
10.6.2. By Sample
10.6.3. By End-user
10.6.4. By Country
11. Europe Lyme Disease Diagnostics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Diagnostic Test, 2017-2031
11.2.1. Serological Test
11.2.1.1. ELISA
11.2.1.2. Western Blot
11.2.2. Polymerase Chain Reaction (PCR) test
11.2.3. Others
11.3. Market Value Forecast, by Sample, 2017-2031
11.3.1. Blood
11.3.2. Cerebrospinal Fluid (CSF)
11.3.3. Others
11.4. Market Value Forecast, by End-user, 2017-2031
11.4.1. Hospitals
11.4.2. Diagnostic Laboratories
11.4.3. Others
11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Diagnostic Test
11.6.2. By Sample
11.6.3. By End-user
11.6.4. By Country/Sub-region
12. Asia Pacific Lyme Disease Diagnostics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Diagnostic Test, 2017-2031
12.2.1. Serological Test
12.2.1.1. ELISA
12.2.1.2. Western Blot
12.2.2. Polymerase Chain Reaction (PCR) test
12.2.3. Others
12.3. Market Value Forecast, by Sample, 2017-2031
12.3.1. Blood
12.3.2. Cerebrospinal Fluid (CSF)
12.3.3. Others
12.4. Market Value Forecast, by End-user, 2017-2031
12.4.1. Hospitals
12.4.2. Diagnostic Laboratories
12.4.3. Others
12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Diagnostic Test
12.6.2. By Sample
12.6.3. By End-user
12.6.4. By Country/Sub-region
13. Latin America Lyme Disease Diagnostics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Diagnostic Test, 2017-2031
13.2.1. Serological Test
13.2.1.1. ELISA
13.2.1.2. Western Blot
13.2.2. Polymerase Chain Reaction (PCR) test
13.2.3. Others
13.3. Market Value Forecast, by Sample, 2017-2031
13.3.1. Blood
13.3.2. Cerebrospinal Fluid (CSF)
13.3.3. Others
13.4. Market Value Forecast, by End-user, 2017-2031
13.4.1. Hospitals
13.4.2. Diagnostic Laboratories
13.4.3. Others
13.5. Market Value Forecast, by Country/Sub-region, 2017-2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Diagnostic Test
13.6.2. By Sample
13.6.3. By End-user
13.6.4. By Country/Sub-region
14. Middle East & Africa Lyme Disease Diagnostics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Diagnostic Test, 2017-2031
14.2.1. Serological Test
14.2.1.1. ELISA
14.2.1.2. Western Blot
14.2.2. Polymerase Chain Reaction (PCR) test
14.2.3. Others
14.3. Market Value Forecast, by Sample, 2017-2031
14.3.1. Blood
14.3.2. Cerebrospinal Fluid (CSF)
14.3.3. Others
14.4. Market Value Forecast, by End-user, 2017-2031
14.4.1. Hospitals
14.4.2. Diagnostic Laboratories
14.4.3. Others
14.5. Market Value Forecast, by Country/Sub-region, 2017-2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Diagnostic Test
14.6.2. By Sample
14.6.3. By End-user
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player – Competition Matrix (By Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2022)
15.3. Company Profiles
15.3.1. LabCorp
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Product Portfolio
15.3.1.3. Financial Overview
15.3.1.4. SWOT Analysis
15.3.1.5. Strategic Overview
15.3.2. Quest Diagnostics
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Product Portfolio
15.3.2.3. Financial Overview
15.3.2.4. SWOT Analysis
15.3.2.5. Strategic Overview
15.3.3. Abbott Laboratories
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Product Portfolio
15.3.3.3. Financial Overview
15.3.3.4. SWOT Analysis
15.3.3.5. Strategic Overview
15.3.4. Bio-Rad Laboratories, Inc.
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Product Portfolio
15.3.4.3. Financial Overview
15.3.4.4. SWOT Analysis
15.3.4.5. Strategic Overview
15.3.5. bioMérieux SA
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Product Portfolio
15.3.5.3. Financial Overview
15.3.5.4. SWOT Analysis
15.3.5.5. Strategic Overview
15.3.6. DiaSorin S.p.A.
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Product Portfolio
15.3.6.3. Financial Overview
15.3.6.4. SWOT Analysis
15.3.6.5. Strategic Overview
15.3.7. T2 Biosystems, Inc.
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Product Portfolio
15.3.7.3. Financial Overview
15.3.7.4. SWOT Analysis
15.3.7.5. Strategic Overview
15.3.8. F. Hoffmann-La Roche AG
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Product Portfolio
15.3.8.3. Financial Overview
15.3.8.4. SWOT Analysis
15.3.8.5. Strategic Overview
15.3.9. Meridian Bioscience, Inc.
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Product Portfolio
15.3.9.3. Financial Overview
15.3.9.4. SWOT Analysis
15.3.9.5. Strategic Overview
15.3.10. Quidel Corporation
15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.10.2. Product Portfolio
15.3.10.3. Financial Overview
15.3.10.4. SWOT Analysis
15.3.10.5. Strategic Overview
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
